Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973680815> ?p ?o ?g. }
- W1973680815 endingPage "18" @default.
- W1973680815 startingPage "3" @default.
- W1973680815 abstract "Objective: Accumulating evidence suggests that the balance between vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and their receptors is important for effective vasculogenesis, angiogenesis, and placental development. Recently, the soluble form of VEGFR-1 (sVEGFR-1), an antagonist to VEGF and PlGF, has been implicated in the pathophysiology of pre-eclampsia. Plasma sVEGFR-1 concentration is elevated in pre-eclampsia at the time of clinical diagnosis and correlates with the severity of the disease. The purpose of this study was to determine whether the concentrations of sVEGFR-1 in plasma of pre-eclamptic patients change prior to the clinical manifestations of the disease.Methods: A longitudinal case-control study was conducted in normal pregnant women (n = 44) and patients with pre-eclampsia (n = 44). Blood sampling was performed at six intervals: (1) 7–16 weeks; (2) 16–24 weeks; (3) 24–28 weeks; (4) 28–32 weeks; (5) 32–36 weeks; and (6) more than 37 weeks of gestation. To examine the relationship between plasma sVEGFR-1 concentration and interval to clinical diagnosis of pre-eclampsia, plasma samples of pre-eclamptic patients at different gestational ages were stratified according to the interval from blood sampling to clinical development of the disease into five groups: (1) at clinical manifestation; (2) 2–5 weeks; (3) 6–10 weeks; (4) 11–16 weeks; and (5) 17–25 weeks before clinical manifestations. Plasma concentrations of sVEGFR-1 were determined by enzyme-linked immunoassay. Parametric statistics and repeated measure procedures were used for the analysis.Results: The mean plasma sVEGFR-1 concentration in pre-eclamptic patients before the clinical manifestation of the disease was significantly higher than in normal pregnant women at 24–28, 28–32, and 32–37 weeks of gestation (p = 0.02, p < 0.001, and p < 0.001, respectively). In contrast, no significant differences in the mean plasma sVEGFR-1 concentration between patients with pre-eclampsia and normal pregnant women were observed both at 7–16 weeks and 16–24 weeks of gestation (p = 0.1 and p = 0.9). Similarly, the mean plasma sVEGFR-1 concentration was significantly higher in pre-eclamptic patients than in normal pregnant women at clinical manifestation, at 2–5 weeks (mean 3.8 weeks), and at 6–10 weeks (mean 8.2 weeks) prior to the development of clinical pre-eclampsia (p < 0.001, p < 0.001, and p = 0.002, respectively). Among patients with early-onset pre-eclampsia (defined as gestational age of 34 weeks or less), the mean plasma sVEGFR-1 concentration was significantly higher in pre-eclampsia (before clinical diagnosis) than in normal pregnant women at 24–28 (mean 26.4) weeks of gestation (p = 0.008). In contrast, among patients with the late-onset disease (defined as gestational age of more than 34 weeks), plasma sVEGFR-1 concentration in pre-clinical pre-eclampsia was significantly higher than in normal pregnant women at 28–32 (mean 30.2) weeks of gestation (p < 0.001).Conclusions: Plasma sVEGFR-1 concentration is elevated in pre-eclampsia prior to the clinical diagnosis of the disease. This elevation began 6–10 weeks prior to the clinical manifestations, and the increase was more pronounced at 2–5 weeks before the diagnosis, as well as at clinical presentation. Furthermore, in early-onset pre-eclampsia, plasma concentration of sVEGFR-1 is elevated earlier than the late-onset disease." @default.
- W1973680815 created "2016-06-24" @default.
- W1973680815 creator A5004871386 @default.
- W1973680815 creator A5021873236 @default.
- W1973680815 creator A5031943261 @default.
- W1973680815 creator A5032961249 @default.
- W1973680815 creator A5041069977 @default.
- W1973680815 creator A5056057196 @default.
- W1973680815 creator A5056581142 @default.
- W1973680815 creator A5059129279 @default.
- W1973680815 creator A5059435570 @default.
- W1973680815 creator A5067511554 @default.
- W1973680815 creator A5089958592 @default.
- W1973680815 date "2005-01-01" @default.
- W1973680815 modified "2023-10-16" @default.
- W1973680815 title "Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia" @default.
- W1973680815 cites W125935861 @default.
- W1973680815 cites W1522285441 @default.
- W1973680815 cites W1540821931 @default.
- W1973680815 cites W1666120340 @default.
- W1973680815 cites W1875554126 @default.
- W1973680815 cites W1955529975 @default.
- W1973680815 cites W1964005024 @default.
- W1973680815 cites W1967961326 @default.
- W1973680815 cites W1971222830 @default.
- W1973680815 cites W1978106524 @default.
- W1973680815 cites W1979071912 @default.
- W1973680815 cites W1980247868 @default.
- W1973680815 cites W1980753244 @default.
- W1973680815 cites W1980909719 @default.
- W1973680815 cites W1980916601 @default.
- W1973680815 cites W1980969801 @default.
- W1973680815 cites W1981620045 @default.
- W1973680815 cites W1983823691 @default.
- W1973680815 cites W1985379157 @default.
- W1973680815 cites W1991827804 @default.
- W1973680815 cites W1992338344 @default.
- W1973680815 cites W1993424990 @default.
- W1973680815 cites W1999090873 @default.
- W1973680815 cites W1999675987 @default.
- W1973680815 cites W2000519828 @default.
- W1973680815 cites W2011722454 @default.
- W1973680815 cites W2012852444 @default.
- W1973680815 cites W2014388753 @default.
- W1973680815 cites W2015058903 @default.
- W1973680815 cites W2016710291 @default.
- W1973680815 cites W2016906744 @default.
- W1973680815 cites W2022803022 @default.
- W1973680815 cites W2023702153 @default.
- W1973680815 cites W2025961381 @default.
- W1973680815 cites W2026038921 @default.
- W1973680815 cites W2026737327 @default.
- W1973680815 cites W2027674323 @default.
- W1973680815 cites W2028217558 @default.
- W1973680815 cites W2031806851 @default.
- W1973680815 cites W2037320667 @default.
- W1973680815 cites W2037730388 @default.
- W1973680815 cites W2038387069 @default.
- W1973680815 cites W2038545399 @default.
- W1973680815 cites W2038628504 @default.
- W1973680815 cites W2045364600 @default.
- W1973680815 cites W2051563676 @default.
- W1973680815 cites W2052889813 @default.
- W1973680815 cites W2053976090 @default.
- W1973680815 cites W2054621026 @default.
- W1973680815 cites W2054970657 @default.
- W1973680815 cites W2056217977 @default.
- W1973680815 cites W2057759012 @default.
- W1973680815 cites W2060697378 @default.
- W1973680815 cites W2061951878 @default.
- W1973680815 cites W2063801308 @default.
- W1973680815 cites W2064373198 @default.
- W1973680815 cites W2067511833 @default.
- W1973680815 cites W2068065161 @default.
- W1973680815 cites W2071924384 @default.
- W1973680815 cites W2075073662 @default.
- W1973680815 cites W2075694732 @default.
- W1973680815 cites W2077070875 @default.
- W1973680815 cites W2077940084 @default.
- W1973680815 cites W2079249388 @default.
- W1973680815 cites W2079724208 @default.
- W1973680815 cites W2080756828 @default.
- W1973680815 cites W2081734842 @default.
- W1973680815 cites W2082057874 @default.
- W1973680815 cites W2082499845 @default.
- W1973680815 cites W2084586130 @default.
- W1973680815 cites W2089162288 @default.
- W1973680815 cites W2090963644 @default.
- W1973680815 cites W2091003012 @default.
- W1973680815 cites W2091816127 @default.
- W1973680815 cites W2091931044 @default.
- W1973680815 cites W2093049135 @default.
- W1973680815 cites W2093830639 @default.
- W1973680815 cites W2094141675 @default.
- W1973680815 cites W2095217306 @default.
- W1973680815 cites W2103545541 @default.
- W1973680815 cites W2106287060 @default.
- W1973680815 cites W2106682905 @default.